Amid the second wave of coronavirus in India, there has been a high demand for Inj. Tocilizumab 400 mg. However, its availability in India has been very low.
Meanwhile, the Punjab Government has issued an order to use Inj. Itolizumab or Inj. Dexamethasone instead of Inj. Tocilizumab 400 mg.
“Number of COVID positive patients admitted at L2 and L3 facilities in the government and the private health facilities have increased sharply over the last few days,” the Punjab government stated.
“It has been observed that the doctors are prescribing Inj. Tocilizumab 400 mg to the patients. It is a matter of common knowledge that Inj. Tocilizumab 400 mg is not manufactured in India and its availability in the country is very low,” it added.
It further stated that “Experts have recommended that since this drug is not easily available, the doctors treating critically ill patients are advised to prescribe the drugs which are available in the market and are equally effective i.e Inj. Itolizumab or Inj. Dexamethasone as per protocol recommended by the experts’ group headed by Dr. KK Talwar, Adviser Health and Medical Education to the Government of Punjab.”
India has been dealing with the second wave of coronavirus with over 3 lakh new cases daily for the past few weeks.
Click here to follow PTC News on Twitter